Meet the team

Founded by scientists

TileBio was founded by a team of scientists with a shared passion for advancing pathology through AI. Our combined expertise spans artificial intelligence, pathology, oncology, and biomedical research.

The founding team brings together decades of experience in medical research, clinical pathology, computational science, and biotech innovation. By uniting these disciplines, we are building foundation models that unlock the visual language of pathology, transforming diagnostics, biomarker discovery, and drug development.

Our vision is to scale our AI model's learning to millions of patient samples worldwide, enabling earlier detection, more accurate prognoses, and breakthroughs in personalised medicine, and pharmaceutical research.

The team

• 

  Christopher Walsh

  Co-Founder / CEO & CTO — AI researcher and entrepreneur specialising in self-supervised learning for digital pathology. With a background spanning biomedical research, oncology, and AI infrastructure, he brings both technical and strategic leadership to TileBio’s mission of unlocking new biology and improving patient outcomes.

• 

  Ke Yuan

  Co-Founder / CSO — Computer scientist specialising in computational pathology. Ke develops AI models that integrate imaging and sequencing to reveal the interplay between genotype and phenotype. His recent work in histopathology has advanced cancer diagnosis and prognosis, and at TileBio he leads scientific strategy, building next-generation frameworks to accelerate translational research.

• 

  David Chang

  Co-Founder / CMO — Professor of Surgical Oncology and Consultant Surgical Oncologist. David combines clinical practice with research in molecular pathology and precision oncology. At TileBio, he guides clinical strategy, ensuring our AI innovations align with real-world challenges and deliver impact for patients and clinicians.

• 

  John Le Quesne

  Co-Founder / CMO — Professor of Molecular Pathology with expertise in AI-driven cancer biology and biomarker discovery. John focuses on extracting quantitative insights from tumour pathology across H&E and advanced spatial methods. At TileBio, he leads clinical translation, ensuring our models are robust, interpretable, and directly relevant to patient care.